printBIO recently hosted the 15th annual BIO CEO & Investor Conference [2] at the Waldorf Astoria New York, the largest investor conference focused on established and emerging publicly traded and select private biotech companies. This year’s event drew more than 1,200 industry leaders, welcomed over 750 investors and facilitated at least 1,300 One-on-One Partnering meetings. BIO’s successful portfolio of investor conferences includes the BIO Investor Forum [3] taking place in San Francisco later this year.
Mark your calenders for next year: Feburary 10th - 11th, 2014. [2]
Celgene CEO on New Multiple Myeloma Drug Approvals [4]
FDA approval of Pomalyst is a big advancement for patients and the drug is very complementary to Celgene’s current myeloma program, Hugin explained.
Word on the Street – Biotech Stocks Only Have Room to Go Up [5]
When evaluating a stock and its market value, the need for access to the best and most current information is crucial.
How to Survive the Patent Cliff: Eli Lilly’s CEO at the BIO CEO & Investor Conference [6]
Like a number of companies, Eli Lilly is confronting a wave of patent expirations called the patent cliff.
Small Biotech Companies and China: 5 Keys to Success [7]
“Relationship building takes very, very long. Don’t talk about any transaction within the first 6 months,” Zhang said. “You have to dine and wine… and sometimes you have to do karaoke!”
Onyx CEO One of 25 Most Influential People in Biopharm Today According to FierceBiotech [8]
Coles contributes a majority of Onyx’s success to two things: a strong mix of collaborations which has allowed business to move rapidly and the continued effort to remain opportunistic.
Look at this post panel mob scene! I was not exaggerating w/ the rockstar part #BIOCEO13 [9] #rarediseasepanel [10] twitter.com/Maybs321/statu… [11]
— Marissa Maybee (@Maybs321) February 12, 2013 [12]
The signing of FDASIA by President Obama in July reinforces the country's commitment to fostering innovation for rare diseases. With a record 460 medicines in late-stage clinical trials, biopharmaceutical companies have embraced rare disease medicine and are rapidly developing the pipeline with hopes of achieving the ever elusive blockbuster drug.
Despite Low Funding, Biotech Productivity Remains High In 2013 [13]
“What I’m seeing at Gilead is very interesting… it’s a real explosion in productivity. We’re seeing great molecules coming through in our HCV portfolio. I think I’ve seen some of the best things that will probably never be drugs come out, because I think the field is moving that fast that we won’t need them.”
Putting a Ring on It: Advice on Successful Drug Development Collaborations [14]
Drug development partnerships can look lucrative to small biotechs eager to monetize their discoveries, but, like any relationship, these tie-ups take work and both parties run the risk of ending up in tears…
Mr. Bienaimé joined BioMarin in May 2005 as chief executive officer and member of the board of directors, bringing with him over 25 years of experience in the biotechnology and pharmaceutical industries. Under his leadership, the market capitalization of BioMarin went from around $450 million in May 2005 to over $4.5 billion in the summer of 2012. BioMarin 2012 revenues are anticipated to be approximately $500 million. BioMarin is a fully integrated biopharmaceutical company with over 1000 employees.
The election chips have fallen and the country is gearing up for another four years of economic challenges and political wrangling. With divided government, compromises will be difficult and time consuming to reach, but will be necessary to deal with big issues the U.S. faces.
Glad to join Josh Bolten at #BIOCEO13 [9] to talk tax policy, health reform, & prepping the #sotu [15] with Presidents Clinton & Bush cc @iambiotech [16]
— John Podesta (@johnpodesta) February 12, 2013 [17]
